Prenatal carrier screening for spinal muscular atrophy among Thai pregnant women

3	Chayada Tangshewinsirikul ¹ , Panyu Panburana ¹ , Maneerat Prakobpanich ² , Takol
4	Chareonsirisuthigul ³ , Donniphat Dejsuphong ⁴ , Thipwimol Tim-aroon ⁵ , Chaiyos
5	Khongkhatithum ⁶ , Thanyachai Sura ⁷ , Atchara Tunteeratum ⁷ , Duangrurdee Wattanasirichaigoon ^{5*}
6	¹ Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Faculty of
7	Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
8	² Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol
9	University, Bangkok, Thailand
10	³ Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University,
11	Bangkok, Thailand
12	⁴ Section for Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol
13	University, Bangkok, Thailand
14	⁵ Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Ramathibodi
15	Hospital, Mahidol University, Bangkok, Thailand
16	⁶ Division of Neurology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital,
17	Mahidol University, Bangkok, Thailand
18	⁷ Division of Medical Genetics, Department of Internal Medicine, Faculty of Medicine
19	Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

20	*Corresponding author
21	E-mail: duangrurdee.wat@mahidol.ac.th
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	

36 ABSTRACT

37 Objectives. To investigate the acceptance rate for spinal muscular atrophy (SMA) carrier
38 screening among Thai pregnant women, their attitudes toward the prenatal screening, carrier rate,
39 and the frequencies of *SMN2* copy numbers.

40 **Materials and methods.** Singleton pregnant women who aged ≥ 18 years, with a gestational age 41 of ≤ 14 weeks at their first visit, were invited to participate the study. All participants completed 42 the questionnaire: Section I - demographic data. Then, they received a pre-test group counseling, 43 followed by an offer of SMA carrier testing at no cost and completion of the questionnaire: 44 Section II - awareness and attitudes toward the screening and Section III – reasons for their choosing 'to have' or 'not to have' the screening done. Only those having the test done and 45 undergoing post-test counseling were asked to complete the questionnaire: Section IV – attitudes 46 47 toward the screening process.

Results. We found a high acceptance rate for carrier screening at 91.4% (181/198 participants), a carrier rate of 2.2% (1 in 45), and high frequency of ≤ 2 copies of *SMN2* (98.3%). The preexisting knowledge about SMA was low (30.8%). The majority of participants became realized about the severity of SMA and its burden to the families (94.4%) and agreed to have fetal diagnosis if they were found to be a couple-at-risk (92.4%). Most participants (98%) suggested that SMA carrier screening should be offered to all pregnant women and that the cost of testing should be covered by the government and/or by their health coverage schemes (95.5%).

55 Conclusion. The high acceptance rate and positive attitude toward prenatal SMA carrier was
56 demonstrated among Thai pregnant women. Data from the present study highlight urgent needs

57	for endorsement from professional society and public health policy in advancing the SMA carrier
58	screening program in Thailand.
59	Key words: spinal muscular atrophy, SMA, prenatal, carrier screening, attitude
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	

73 Introduction

74 Spinal muscular atrophy (SMA) is a severe neuromuscular disorder which results in 75 progressive muscle weakness, with an estimated incidence of 1 in 6,000-10,000 births worldwide 76 [1]. SMA is divided into four clinical types depending on the age of onset and clinical progression. Type I SMA (Werdnig-Hoffmann) has clinical onset within the first three months 77 78 of life, usually leading to respiratory failure and death by two years of age. The onset of type II 79 SMA is 6-18 months of age, and the affected children may sit independently but cannot stand or walk, with 70% surviving beyond 25 years of age. Patients with type III SMA (Kugelberg-80 81 Welander), with the onset at ≥ 18 months, have difficulty climbing stairs and running and often 82 have a normal lifespan. Type IV SMA or adult-onset SMA is described with slow progression of 83 muscle weakness beginning at around 30 years of age, and with no reduction in life expectancy 84 [2]. Type I SMA has the highest incidence among SMA, at 50-60% [2-5]. However, there is a 85 marked difference between incidence and prevalence of type I SMA because of its low survival 86 [6-7]. Among the living individuals with SMA, types II and III together account for 75-83% [6-87 9].

Survival motor neuron 1 (SMN1) gene, located on 5q11.2–q13.3, is the disease-causing 88 89 gene of SMA. Approximately 95-98% of SMA cases are caused by a homozygous deletion of 90 exon 7 or exons 7-8 of the SMN1 gene, with 3%-5% being due to point mutation or compound 91 heterozygosity between the deletion and point mutations [2]. SMN2 is a highly homologous gene 92 of SMN1, they are located next to each other. The complete absence of SMN2 yields no clinical 93 effect on healthy individuals. The copy number of SMN2 rather modifies the severity of SMA [2, 6, 10]. Most people have two copies of SMN1, each on the homologous chromosome, and two 94 95 copies of *SMN2*, each on the homologous chromosome as well [2,11], The higher number of

SMN2 copy number is associated with less severity of the SMA phenotypes (1 copy of SMN2:
96% - type I SMA; 2 copies: 79% - type I; 3 copies: 54% - type II and 31% - type III/IV; ≥4
copies: 88% - type III/IV) [2]. Therefore, simultaneous copy number detection of *SMN1*-exon 7
(or exons 7-8) and *SMN2*-exon7 is widely used for molecular diagnosis and prognostication for
SMA [2,12]. As for carrier screening in general population, copy number analysis of the *SMN1* is
a preferred method, owing to its high throughput, rapid turn-around time, and economical reason
[13-15].

Carrier frequency of SMA in general population is high at approximately 1 in 33-94
worldwide [2, 11, 13, 15, 16], and potentially with the most severe phenotype due to the high
frequency of ≤2 copies of *SMN2* among the carriers [15, 17-21]. Screening for SMA carrier
before conception or early in pregnancy, regardless of religion or ethnicity, has been
recommended by the American College of Medical Genetics (2008) and by the American
College of Obstetricians and Gynecology (2017) [22, 23].

109 Thailand is a middle-income country with well-established universal health coverage 110 (UHC) since 2002 (https://eng.nhso.go.th/) Almost all Thai citizens are currently covered by one 111 of the three health benefit schemes: 74% under the Thai UHC, 7% covered by the Civil Servant 112 Medical Benefit Scheme (CSMBS, for government/state employees), and 19% under the Social 113 Security Scheme (SSS for working adults). Notably, 93% of Thai Children are covered by the 114 UHC. Prenatal screening for thalassemia (carrier rate 40%) has been offered as the national 115 policy since 1992, with a good coverage at 98% of pregnant women [24, 25]. Carrier frequency 116 of SMA among Thai population is 1 in 40 [26, 27], but SMA carrier screening is not included in 117 the national program or routine antenatal care in the country. Newborn screening for SMA is not 118 offered and specific treatments for SMA (such as mRNA-modifying treatment and gene therapy) is not reimbursable under the existing health schemes in the country. Carrier testing for SMA and
reproductive choices are offered to only the families with previous affected child/relatives with
SMA.

To explore the potentials for establishing carrier screening for SMA during prenatal period, we set off to conduct this study. Our objectives were to assess the acceptance rate of the carrier screening among Thai pregnant women, to evaluate their attitudes toward the screening, to determine the prevalence of SMA carrier and the frequencies of *SMN2* copy numbers.

126 Materials and Methods

127 Study design and participants

This was a prospective and descriptive study, conducted during 10 March 2021 and 31 March 2022, at the antenatal care clinic, Ramathibodi Hospital. The protocol was granted by the Ramathibodi Hospital Institutional Review Board (COA, MURA2020/1420) and complied with the Declaration of Helsinki. The study was registered as a clinical trial (registration number NCT04859179).

Eligible participants were women with singleton pregnancy, who were aged ≥ 18 years and capable of reading and understanding Thai, and with a gestational age of ≤ 14 weeks at their first visit with our antenatal care clinic. They were invited to enroll in the study, by one of the authors (MP) and asked to provide a written informed consent. Exclusion criteria were refusal to give a written consent, withdrawal during or after the completion of the study, and insufficient data obtained from the questionnaire.

139 Questionnaire

A Thai-language questionnaire was developed using information from a literature review,
then validated by six clinical experts: two maternal and fetal medicine specialists, two pediatric
geneticists, and two clinical scientists. The reliability of the questionnaire was 0.797, as assessed
by using Cronbach's alpha.

144 The questionnaire contained four sections, I-IV. Section I focused on the participants' 145 demographic data, including age, education, occupation, religion, and gravida and previous 146 history of fetal anomalies. Section II asked about awareness and attitudes toward SMA carrier 147 screening. This section comprised of nine question items, including the awareness of severity of 148 SMA and its burden on the patients and families, the usefulness and interest in having prenatal 149 carrier screening for SMA and their confidence in the reliability of the test offered, agreement in 150 having definitive test for fetal diagnosis, possible considering termination of pregnancy as an 151 alternative if the fetus to be found affected, opinion on having SMA carrier screening as part of a 152 standard antenatal care, and their willingness to self-pay for the screening test. The answer 153 options were 'agree', 'not sure', and 'disagree'.

As for Section III, we explored the reason(s) and/or rationale thinking of the participants for choosing 'to have' or 'not to have' the carrier screening test. Multiple choice answers were provided to choose and the participants could choose more than one answer as wanted. We also asked the participants' opinions on a reasonable price for the screening test if it had to be selfpay, and who (individuals, organizations, health schemes, or else), in their opinion, should be responsible for cost of testing if the screening would become part of standard antenatal care in the country.

Section IV consisting five question items, was about the participants' attitudes and
 reflections of their immediate past experience with going through the SMA carrier screening

process including pre-test and post-test counselling: overall feeling/satisfaction to the screening process, the usefulness of the information provided, the essence of post-test counseling, the whole process is time worthy, and that the carrier screening should be offered to all pregnant women during antenatal visit. The answer options for each question were 'agree', 'not sure', and 'disagree'.

168 Data collection

169 All the participants, after the completion of Section I of the questionnaire, were provided with pre-test group counseling delivered by trained maternal and fetal medicine specialists using 170 171 a PowerPoint presentation which lasted for about 10 minutes. The participants then received the 172 Thai-language brochure to read in a designated area, this was to allow the participants time to 173 digest the information received and self-check of their understanding. The slide presentation for 174 the group counseling and the brochure contained similar information, including the incidence, 175 clinical presentations, natural course and outcomes of SMA; treatment options and the efficacy 176 of available treatments, affordability of the treatment in the country; carrier rate and carrier 177 screening; and prenatal diagnosis and its downstream services.

After pre-test counseling, a free-of-charge SMA carrier testing (as part of this research) was offered to all participants and they were asked to complete the questionnaire Sections II and III, regardless of their choosing to have the test done or not. A sequential prenatal SMA carrier screening protocol was established to use in this research (Figure 1). For those choosing not to have the test done, the study ended at this point. About those choosing to have carrier testing performed, 10-ml of venous blood sample was taken for *SMN1* and *SMN2* analysis. Post-test counseling for each individual was offered by a maternal and fetal medicine specialist at an antenatal care clinic, upon the result became available. Then, the participants were requested to finalize the Section IV of the questionnaire. For those who were found to be a carrier, their partner was counseled and offered the carrier testing (with no charge). Prenatal diagnosis would be discussed to a couple at risk.

189 *Carrier testing and copy numbers analysis for SMN1 and SMN2*

190 To detect copy number of SMN1 and SMN2, we performed multiple ligation-dependent probe amplification (MLPA) analysis, using a commercially available MLPA kit for SMA 191 192 (SALSA P021), following the manufacturer's protocol (MRC Holland, Amsterdam, the 193 Netherlands). The MLPA reactions included internal quality controls and negative controls. The 194 PCR products were analyzed using the Applied Biosystems 3500 Genetic Analyzer 195 (Thermofisher Scientific, MA, USA) and Coffalyser.net software (MRC Holland), following the 196 manufacturer's instructions. The tests were performed at the Human Genetics Laboratory, 197 Ramathibodi Hospital. Carrier status, in the present study, is defined as having only 1 copy of 198 SMN1 exon 7. The results of carrier testing were reported to the clinician researchers (CT, PP, 199 and MP) within two weeks.

200 Statistical analyses

201 Categorical variables were described as the number (percent). Parametric continuous202 variables were expressed as a mean and standard deviation.

203 Results

A total of 237 pregnant women were assessed, 35 did not meet the inclusion criteria and four declined to participate, leaving 198 (83.5%) of eligible participants to be enrolled in the study. Among 181 out of 198 (91.4%) research participants who took the screening test, four
were identified as carriers of SMA. Their partners were screened, and none was found to be a
carrier, resulting in no couple at risk detected in the present study (Figure 2).

The mean age of the participants was 32 ± 5.1 years and over half (66.2%) of them had a Bachelor's degree or higher (Table 1). None had a child or family relative(s) with SMA. Twothirds of the participants said that they had never heard of SMA before.

212 Acceptance and attitudes toward SMA carrier screening

213 Around 95% or over of the participants agreed that SMA is a serious disorder resulting in 214 severe life suffering, and that the carrier screening could reduce unnecessary anxiety during pregnancy and it should be offered to all pregnant women (Table 2). About 80-92% or more of 215 216 the participants expressed that having a child with SMA would complicate their life, they were 217 not reluctant to have the screening test done, they had a good faith in the accuracy of the test, and 218 they would have fetal diagnosis if they would be found to be a couple at risk (Table 2). Almost 219 half of the participants expressed their tendency to choose termination of pregnancy for an 220 affected fetus (Table 2).

In the present study, the most common reasons for having the carrier screening included wanting to know their carrier status (87.8%), being worried to have an affected fetus (72.9%), and no extra cost for the test (50.3%) (Table 3). As for those declining the test, they reasoned that SMA was rarely found (58.8%) (Table 3).

Almost half of the participants (47.7%) said that they could afford 501–1,000 Baht (~1428 USD) if self-pay for the SMA carrier screening. Most participants (95.5%) thought that the

cost of carrier testing should be covered by the government and/or their health coverage schemes(Table 4).

After receiving the result of screening test, all the participants expressed the feeling of glad that they had had the test done. They all agreed that the information about SMA provided to them were very useful and that post-test counseling was essential (Table 5).

232 SMA carrier rate and frequencies of SMN2 copy number

Only 2.2% (4/181) of the participants were found to be carrier (Table 6). As for the SMN2, the majority of participants had 2 copies (58.5%), followed by ≤ 1 copy (39.8%), and ≥ 3 copies (1.7%). Regarding the carrier individuals, three had 2 copies and the other had 1 copy of SMN2.

237 Discussion

We found a high acceptance rate for prenatal SMA carrier testing (91.4%) and positive attitudes towards the screening test, among the pregnant women in this study. Most participants (92%) would choose fetal diagnosis if they were found to be a couple at risk and consider having interruption of pregnancy in case of affected fetus (47%), these finding were in agreement with earlier studies [13, 15]. The majority of the participants suggested SMA carrier testing to be part of standard antenatal care and covered by the public health system.

The low awareness of SMA among the participants, were probably due to the rarity of the disorder; being a hidden problem of SMA owing to the short life of significant proportion of the patients, the patients' low social activities because of respiratory and ambulatory difficulties; and the lack of public health education and screening services for SMA [9, 28, 29]. Despite of generally low awareness of SMA prior to the study, the acceptance rate for SMA prenatal carrier screening was high among the participants in the present study, likely due to several factors including the knowledge about SMA given, perceived usefulness of the preand post-test counseling provided, trust in the test offered, testing at no extra cost (Table 3), and availability of the downstream services. Some studies have shown a significantly increased acceptance rate if covered by medical insurance/health scheme (97.8%) compared to self-funded screening (81.1%) [29, 30]. Other influencing factors included race, parity, and religion [17, 29].

As for those declining the screening test, the main reasons were the low prevalence of SMA (58.8%) and not choosing interruption of the pregnancy for an affected fetus (17.6%). Our findings were consistent with previous reports that people without SMA experience had significantly lower rate of taking carrier testing because they had a dimmer view of the condition than those with experiential knowledge [29, 31]. Therefore, the endorsement from public health authority and professional society and effective mass communications are urgently needed in advancing the SMA carrier screening program [29-31].

The SMA carrier rate found in this study was 1 in 45, with estimated prevalence of SMA at 1 in 8,264, similar to those found worldwide [11, 13, 15, 16, 17-21, 26, 27]. The majority (98.3%) of the participants had ≤ 2 copies of *SMN2*, suggesting that a major proportion of Thai affected individuals (fetuses) would be predicted to have the most severe phenotype (type I) of SMA, consistent with other studies [2, 11].

To establish a new prenatal carrier screening program in any country, it is essential to have testing that is acceptable to the target population, with timely turnaround time, appropriate pre-test and post-test counseling, and affordable downstream services including testing for the partners, fetal diagnosis, and choices of continuation and interruption of pregnancy. Other local context, such as affordable treatment and predicted severity of the disorder, would also
tremendously influence the individual's decision on taking or declining the testing. Therefore,
population-specific data, both biomedical (carrier rate, copy number of *SMN2*, type of SMA,
availability of specific treatment) and sociocultural aspect (religion and extended socioeducational supports) are highly essential for policy planning for each country.

SMA fits all the criteria for prenatal carrier screening, as follows: 1) severity of the
disorder; 2) high carrier frequency in the general population more than 1 in 100; 3) available
carrier screening test with a high sensitivity and specificity; 4) availability of prenatal diagnosis
during early gestation; and 5) timely turnaround time for the screening test and fetal diagnosis
[22, 28].

The impact of population-based carrier screening for SMA has been well shown in Israel by that 31% of the cases were prenatally diagnosed following the introduction of the screening through healthcare service and insurance plans (since 2008), and even higher at 52% after it became the national program (since 2013) [30].

To date, Thailand has had a successful prenatal carrier screening program for thalassemia using a sequential testing strategy. Both thalassemia and SMA are inherited in an autosomal recessive fashion. We believe that it is highly pragmatic to incorporate the SMA screening along with thalassemia screening program for Thai population. However, public education of SMA and additional training for healthcare professionals especially those in family medicine and prenatal setting are required. Moreover, the SMA carrier screening can be further expanded to the preconceptional period. 292 To our knowledge, this study is the first study to evaluate the acceptance of prenatal 293 SMA carrier screening and its influencing factors among Thai population, using a prepared set of 294 educational materials and counseling program. The study is one of a very few studies of its kind, 295 among Asian populations and low-middle income countries which is underrepresented in the 296 literature. The validated Thai-language brochure and the whole process of testing strategy which 297 were approved for its usefulness by the participants could be applied to a large-scale screening 298 among Thai population. Lastly, this is the first demonstration of copy number of SMN2 among 299 general population of Thais.

300 The authors appreciated limitations of the study, including a small sample size, the 301 absence of couples at risk and affected fetus identified, which might have resulted in different 302 answers on choosing fetal diagnosis and pregnancy outcome.

303 Conclusion

The acceptance rate for prenatal SMA carrier screening was high among Thai pregnant women and it could be further amplified by effective mass education to general population and affordable screening services. The estimated prevalence and carrier frequency of SMA among Thai population was found equivalent to the worldwide data and the majority of patients were predicted to have the most severe type of SMA, necessitating the needs for national program for disease prevention. Population-specific data, both biomedical and sociocultural aspects, are markedly important for national policy planning for the carrier screening.

311 Acknowledgements

312	We are thankful of the Faculty of Medicine Ramathibodi Hospital, Mahidol University for
313	providing Research Career Development Awards to DW, TT, and DD. We thank Melissa
314	Leffler, MBA, from Edanz (www.edanz.com/ac) for editing a draft of this manuscript.
315	Authors' contributions
316	Conceptualization: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul, Donniphat
317	Dejsuphong, Duangrurdee Wattanasirichaigoon
318	Data curation: Chayada Tangshewinsirikul, Maneerat Prakobpanich, Takol Chareonsirisuthigul
319	Formal analysis: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul, Duangrurdee
320	Wattanasirichaigoon
321	Funding Acquisition: Chayada Tangshewinsirikul
322	Investigation: Chayada Tangshewinsirikul, Panyu Panburana, Maneerat Prakobpanich, Takol
323	Chareonsirisuthigul, Donniphat Dejsuphong, Thipwimol Tim-aroon, Duangrurdee
324	Wattanasirichaigoon
325	Methodology: Chayada Tangshewinsirikul, Panyu Panburana, Maneerat Prakobpanich, Takol
326	Chareonsirisuthigul, Donniphat Dejsuphong, Thipwimol Tim-aroon, Chaiyos Khongkhatithum,
327	Thanyachai Sura, Atchara Tunteeratum, Duangrurdee Wattanasirichaigoon
328	Supervision: Duangrurdee Wattanasirichaigoon
329	Writing- original draft: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul
330	Writing-review & editing: Duangrurdee Wattanasirichaigoon
331	Data availability statement

332	The datase	ets generated and/or analyzed during the current study are not publicly available due to	
333	limitations	s of ethical approval involving the patient data and anonymity but are available from	
334	the corresp	ponding author on reasonable request.	
335	Funding		
336	This resear	rch was supported by grants from Faculty of Medicine Ramathibodi Hospital, Mahidol	
337	University, Bangkok, Thailand (Grant ID RF_64035). The funders had no role in the study		
338	design, dat	ta collection and analysis, decision to publish, or preparation of the manuscript.	
339	Competin	ig interests	
340	The author	rs declare that they have no competing interests.	
341	Figure legends		
342	Figure 1 S	Sequential prenatal spinal muscular atrophy (SMA) carrier screening protocol	
343	Figure 2 F	Prenatal carrier screening among 198 pregnant women	
344	Reference		
345	1.	Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood	
346		spinal muscular atrophy. J Med Genet. 1978;15(6):409-13.	
347	2.	Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24 [Updated	
348		2020 Dec 3]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews®	
349		[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available	
350		from: https://www.ncbi.nlm.nih.gov/books/NBK1352/	

351	3.	Rashnonejad A, Onay H, Atik T, Atan Sahin O, Gokben S, Tekgul H, et al. Molecular
352		Genetic Analysis of Survival Motor Neuron Gene in 460 Turkish Cases with
353		Suspicious Spinal Muscular Atrophy Disease. Iran J Child Neurol. 2016;10(4):30-5.
354	4.	Verhaart IEC, Robertson A, Leary R, McMacken G, König K, Kirschner J, et al. A
355		multi-source approach to determine SMA incidence and research ready population. J
356		Neurol. 2017;264(7):1465-73.
357	5.	Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2
358		region: simulation and meta-analysis for allele and haplotype frequency calculations.
359		Eur J Hum Genet. 2004;12(12):1015-23.
360	6.	Coratti G, Ricci M, Capasso A, D'Amico A, Sansone V, Bruno C, et al. Prevalence of
361		Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian
362		Nationwide Survey. Neurology. 2023;100(11):522-8.
363	7.	Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation
364		of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.
365		Orphanet J Rare Dis. 2017;12(1):175.
366	8.	Arikan Y, Berker Karauzum S, Uysal H, Mihci E, Nur B, Duman O, et al. Evaluation
367		of exonic copy numbers of SMN1 and SMN2 genes in SMA. Gene.
368		2022;823:146322.
369	9.	Aksaralikitsunti M, Sanmaneechai O. Health-related quality of life in Thai children
370		with spinal muscular atrophy. Pediatr Neonatol. 2022;63(3):291-7.
371	10.	Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al. Molecular
372		analysis of spinal muscular atrophy and modification of the phenotype by SMN2.
373		Genet Med. 2002;4(1):20-6.

- 374 11. Zhao S, Wang W, Wang Y, Han R, Fan C, Ni P, et al. NGS-based spinal muscular 375 atrophy carrier screening of 10,585 diverse couples in China: a pan-ethnic study. Eur 376 J Hum Genet. 2021;29(1):194-204. 377 12. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy 378 (SMA). Hum Genet. 2002;111(6):477-500. 13. Sun Y, Ma S, Xiao J, Wu J, Wu Y, Shi X, et al. Preconception or prenatal acceptance 379 380 of SMN1 gene carrier screening and carrier rate of spinal muscular atrophy: a 381 retrospective study in 18,818 reproductive age women in Wuhan area of China. J 382 Assist Reprod Genet. 2024;41(1):127-33. 383 14. Tan J, Zhang J, Sun R, Jiang Z, Wang Y, Ma D, et al. Evaluating the performance of 384 four assays for carrier screening of spinal muscular atrophy. Clin Chim Acta. 385 2023;548:117496. 386 15. Huang Z, Yang Q, Ye J, Huang J, Lin J, Chen J, et al. Screening and prenatal
- diagnosis of survival motor neuron gene deletion in pregnant women in Zhaoqing
 city, Guangdong Province. BMC Med Genomics. 2023;16(1):39.
- 389 16. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic
 390 carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical
- laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27-32.
- Wood SL, Brewer F, Ellison R, Biggio JR, Edwards RK. Prenatal Carrier Screening
 for Spinal Muscular Atrophy. Am J Perinatol. 2016;33(12):1211-7.
- Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of
 SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier

396		testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet.
397		2002;70(2):358-68.
398	19.	Cusin V, Clermont O, Gérard B, Chantereau D, Elion J. Prevalence of SMN1 deletion
399		and duplication in carrier and normal populations: implication for genetic
400		counselling. J Med Genet. 2003;40(4):e39.
401	20.	Hendrickson BC, Donohoe C, Akmaev VR, Sugarman EA, Labrousse P,
402		Boguslavskiy L, et al. Differences in SMN1 allele frequencies among ethnic groups
403		within North America. J Med Genet. 2009;46(9):641-4.
404	21.	Smith M, Calabro V, Chong B, Gardiner N, Cowie S, du Sart D. Population screening
405		and cascade testing for carriers of SMA. Eur J Hum Genet. 2007;15(7):759-66.
406	22.	Prior TW. Carrier screening for spinal muscular atrophy. Genet Med.
407		2008;10(11):840-2.
408	23.	Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet
409		Gynecol. 2017;129(3):e41-e55.
410	24.	Wanapirak C, Tongsong T, Sirivatanapa P, Sa-nguansermsri T, Sekararithi R,
411		Tuggapichitti A. Prenatal strategies for reducing severe thalassemia in pregnancy. Int
412		J Gynaecol Obstet. 1998;60(3):239-44.
413	25.	Paiboonsukwong K, Jopang Y, Winichagoon P, Fucharoen S. Thalassemia in
414		Thailand. Hemoglobin. 2022;46(1):53-7.
415	26.	Dejsuphong D, Taweewongsounton A, Khemthong P, Chitphuk S, Stitchantrakul W,
416		Sritara P, et al. Carrier frequency of spinal muscular atrophy in Thailand. Neurol Sci.
417		2019;40(8):1729-32.

418	27.	Chaisomchit S, Thongnoppakhun W, Pho-iam T, Limwongse C, Likasitwattanakul S,
419		Chareonsiriwatana W, et al. Investigation of carrier frequency for spinal muscular
420		atrophy in Thailand using dried blood spot specimens. Genomics and Genetics.
421		2016;9(2&3): 78-84.
422	28.	Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and
423		carrier screening for spinal muscular atrophy. Am J Med Genet A.
424		2010;152a(7):1608-16.
425	29.	Li Y, Wang L, Tan J, Huang M, Wang Y, Shao B, et al. Current attitudes toward
426		carrier screening for spinal muscular atrophy among pregnant women in Eastern
427		China. J Genet Couns. 2023;32(4):823-32.
428	30.	Aharoni S, Nevo Y, Orenstein N, Basel-Salmon L, Ben-Shachar S, Mussaffi H, et al.
429		Impact of a national population-based carrier-screening program on spinal muscular
430		atrophy births. Neuromuscul Disord. 2020;30(12):970-4.
431	31.	Boardman FK, Young PJ, Warren O, Griffiths FE. The role of experiential knowledge
432		within attitudes towards genetic carrier screening: A comparison of people with and
433		without experience of spinal muscular atrophy. Health Expect. 2018;21(1):201-11.
434		
435		

Sequential prenatal SMA carrier screening protocol







Figure 2 Prenatal carrier screening among 198 pregnant women

Figure